Psychiatry and Neurology, Neurology · Boston, MA
NPI
1780646349
Since 2006
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
3
Medicare group memberships
Hospitals
1
Hospital affiliations
725 Albany Street, Shapiro 7, Suite B
Boston, MA, 02118
Phone (617) 638-8456
Groups this clinician bills Medicare through
Medicare paid, 2024
$46K
705 services
Medicare patients, 2024
234
Average age 72
Drug cost, 2024
$2.6M
2,052 prescriptions
Company payments, 2025
$22K
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Samuel A Frank was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 123 times for 88 patients. In total Samuel A Frank billed 705 services in 27 codes, and Medicare paid $46K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-07-25.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 123 | 88 | $13.15 | $1,617 |
| 99214 Office E&M - Established | Facility | 116 | 80 | $71.75 | $8,324 |
| 64616 Musculoskeletal | Facility | 108 | 36 | $120.39 | $13K |
| 95874 Musculoskeletal | Facility | 57 | 25 | $14.47 | $825 |
| 99213 Office E&M - Established | Facility | 47 | 40 | $47.57 | $2,236 |
| 64612 Musculoskeletal | Facility | 44 | 20 | $112.33 | $4,942 |
| 64642 Musculoskeletal | Facility | 29 | 15 | $84.19 | $2,441 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 23 | 17 | $13.22 | $304 |
| 99214 Office E&M - Established | Office | 20 | 18 | $105.65 | $2,113 |
| 99213 Office E&M - Established | Office | 20 | 18 | $64.24 | $1,285 |
| 99215 Office E&M - Established | Facility | 19 | 18 | $106.45 | $2,022 |
By year: 2022 $54K for 669 services; 2023 $50K for 593 services; 2024 $46K for 705 services.
Medicare prescription drug claims, 2024
In 2024, the drug Samuel A Frank prescribed most often to Medicare patients was Carbidopa-Levodopa (Carbidopa/Levodopa), with 245 prescriptions and refills. In total Samuel A Frank wrote 2,052 Medicare prescriptions that cost $2.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Carbidopa-Levodopa Carbidopa/Levodopa | 245 | 623 | 75 | $9,632 |
| Carbidopa-Levodopa Er Carbidopa/Levodopa | 153 | 367 | 37 | $7,097 |
| Clonazepam Generic | 129 | 169 | 23 | $1,445 |
| Austedo Deutetrabenazine | 90 | 90 | Under 11 | $1.0M |
| Rasagiline Mesylate Generic | 88 | 232 | 26 | $23K |
| Ingrezza Valbenazine Tosylate | 86 | 103 | Under 11 | $915K |
| Pramipexole Dihydrochloride Pramipexole Di-Hcl | 78 | 188 | 21 | $1,619 |
| Rytary Carbidopa/Levodopa | 69 | 154 | 19 | $132K |
| Mirtazapine Generic | 68 | 152 | 16 | $1,494 |
| Entacapone Generic | 60 | 156 | 17 | $18K |
| Amantadine Amantadine Hcl | 58 | 162 | 19 | $4,779 |
| Venlafaxine Hcl Er Venlafaxine Hcl | 47 | 136 | 13 | $955 |
| Gabapentin Generic | 45 | 101 | 11 | $784 |
| Carbidopa-Levodopa-Entacapone Carbidopa/Levodopa/Entacapone | 39 | 85 | Under 11 | $13K |
| Rivastigmine Generic | 35 | 80 | Under 11 | $13K |
Brand drugs: - claims; generic drugs: 1,643 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Samuel A Frank $22K ($22K in general payments such as food, travel and fees) from 12 companies. The largest payer was Sanofi US Services Inc. with $6,590.
| Company | Payments | Amount |
|---|---|---|
| Sanofi US Services Inc. SNY | 1 | $6,590 |
| Novartis Pharmaceuticals Corporation NVS | 5 | $6,304 |
| Teva Pharmaceuticals USA, Inc. TEVA | 1 | $3,180 |
| Alnylam Pharmaceuticals Inc. ALNY | 2 | $3,090 |
| F. Hoffmann-La Roche AG ROG.SW | 3 | $2,295 |
| Neurocrine BioSciences, Inc. NBIX | 1 | $58.23 |
| UCB, Inc. UCB.BR | 1 | $49.4 |
| NS Pharma, Inc. | 1 | $21.68 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.